• Biogen to Acquire Nightstar Therapeutics americanpharmaceuticalreview
    March 06, 2019
    Biogen has entered into an agreement to acquire Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
PharmaSources Customer Service